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Schistosome infection is a major cause of global morbidity, particularly in sub-Saharan
Africa. However, there is no effective vaccine for this major neglected tropical disease, and
re-infection routinely occurs after chemotherapeutic treatment. Following invasion through
the skin, larval schistosomula enter the circulatory system and migrate through the lung
before maturing to adulthood in the mesenteric or urogenital vasculature. Eggs released
from adult worms can become trapped in various tissues, with resultant inflammatory
responses leading to hepato-splenic, intestinal, or urogenital disease – processes that have
been extensively studied in recent years. In contrast, although lung pathology can occur in
both the acute and chronic phases of schistosomiasis, the mechanisms underlying
pulmonary disease are particularly poorly understood. In chronic infection, egg-mediated
fibrosis and vascular destruction can lead to the formation of portosystemic shunts through
which eggs can embolise to the lungs, where they can trigger granulomatous disease.
Acute schistosomiasis, or Katayama syndrome, which is primarily evident in non-endemic
individuals, occurs during pulmonary larval migration, maturation, and initial egg-
production, often involving fever and a cough with an accompanying immune cell
infiltrate into the lung. Importantly, lung migrating larvae are not just a cause of
inflammation and pathology but are a key target for future vaccine design. However,
vaccine efforts are hindered by a limited understanding of what constitutes a protective
immune response to larvae. In this review, we explore the current understanding of
pulmonary immune responses and inflammatory pathology in schistosomiasis,
highlighting important unanswered questions and areas for future research.
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Schistosomiasis is a neglected tropical disease, with over 200 million people infected by trematodes
of the Schistosoma genus – S. mansoni, S. haematobium and S. japonicum (1). Infection occurs when
individuals come into contact with water containing cercariae, which infect humans via the skin (2–
4). After skin penetration, cercariae transform into larval schistosomula which enter the
bloodstream, passing through the lungs before maturing in the hepatic portal veins, where males
and females pair and move to either the mesenteric (S. mansoni and S. japonicum) or urogenital
(S. haematobium) vasculature to lay eggs (5). Schistosomiasis can be categorised into acute andorg April 2021 | Volume 12 | Article 6355131
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maturation and initial egg production (6). Symptoms of the acute
phase, most commonly observed in travellers to endemic regions,
include cercarial dermatitis in the days following infection, and
Katayama syndrome, characterised by fever, cough and myalgia,
from week 2 post infection (7). The chronic stage of
schistosomiasis has been proposed to begin, somewhat
arbitrarily, at 12 weeks post infection, with egg-deposition
driving symptoms in multiple organs including the liver,
bladder, and lung (8). Approximately 60% of endemically
infected individuals experience schistosomiasis associated
morbidity, predominantly anaemia and malnutrition, with 10%
severely ill (5, 9, 10). Upon closer inspection, severely ill
individuals often harbour high intensity infections and appear
immunologically inept at regulating the persistent, egg-driven
pathology (11).
Although lung symptoms can occur in both acute and chronic
schistosomiasis, as shown in Figure 1, the aetiology of pulmonaryFrontiers in Immunology | www.frontiersin.org 2pathology in acute schistosomiasis is not well understood (12).
Pulmonary symptoms – shortness of breath, wheezing and dry
cough (13) – can begin before larvae develop to adulthood and
patency (egg production), as early as 2 weeks post infection, and
therefore may be attributable to immune responses to lung
migrating schistosomula (14, 15). Alternatively, at the post-patent
acute stage these same symptoms may be caused by a systemic
immune response to worms or eggs in the mesenteric or urogenital
vasculature (13). In these cases, eosinophils, induced in response to
parasite antigens, may be sequestered in the lungs, observable as
lesions on lung radiographs (15, 16). In chronic schistosomiasis,
potentially years post infection, pulmonary symptoms are better
understood. Eggs, or even adult worms, were identified in the lungs
of patients with chronic disease over 80 years ago (17). Further,
pulmonary egg deposition due to advanced hepatosplenic disease
can lead to potentially fatal pulmonary hypertension (17–23).
The immune response to schistosomiasis changes over the
course of infection, dictated both by developmental changes inFIGURE 1 | Overview of lung immune responses during S. mansoni infection. Lung immune responses differ depending on the life cycle stage of the parasite,
broadly characterised into acute (pre-patent and post-patent) and chronic phases. (A) Pulmonary symptoms vary, with cough and breathlessness during the acute
phase in response to larval migration, maturation, and initial egg production. In chronic disease pulmonary hypertension is the key pulmonary pathology. Lesions may
be observed in lung radiographs in all stages, although with differing aetiology in response to migrating larvae, worms, or eggs. (B) Human immune responses can
be split into acute and chronic infection, often assayed systemically. Broadly, an early eosinophilic response with mixed type-1/type-2 cytokines makes way for a
type-2/regulatory response to schistosome eggs, with tissue granulomas. (C) Murine immune responses can be more accurately demarcated into stage-specific
responses, with a muted type-1/type-2 response to lung migrating larvae making way to a systemically driven dominant type-2 response upon egg production. In
response to pulmonary egg deposition, chronic responses in the lung display type-1/type-2 cytokine production and granulomatous inflammation.April 2021 | Volume 12 | Article 635513
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to long-term infection (24). A classic example of this would be
the onset of patency which, in murine models, provokes a
dramatic increase in Th2 (IL-4 and IL-5) cytokine production
(25). Despite ongoing infection, schistosome antigen
responsiveness (26), and Th2 cytokine production is thought
to peak around week 8-10 post infection, then reduce (27), with a
concurrent increase in regulatory T and B cells, and T cell
hyporesponsiveness (28–31). This shift to an increasingly
regulatory phenotype from about week 12 post infection is
thought to underlie the transition between acute and chronic
schistosomiasis (27). Therefore, where possible, we will use ‘pre-
patent acute’ (0 to 5 weeks post infection), ‘post-patent acute’ (5
to 12 weeks post infection), and ‘chronic’ (>12 weeks post
infection) terminology to refer to the different phases of
infection in this review.
Murine studies have provided valuable insight into the
pulmonary immunological response to acute and chronic
schistosomiasis. During the pre-patent lung migrating stage,
there is some evidence that a pulmonary Th2 response is
initiated (32), with eosinophilic pulmonary infiltrates (14), and
a low-level systemic Th1 response (25, 32). In the patent stage of
infection, pulmonary inflammation is thought to reflect the
exaggerated systemic Th2 responses driven by schistosome
eggs in organs such as the liver (25) until eggs translocate to
the lungs via portal shunts (peaking around week 17), leading to
a similarly Th2 dominated granulomatous response directly in
the lung tissue (33, 34). Since schistosome larvae migrate through
the lungs early in infection (35), a deeper mechanistic
understanding of pulmonary immune responses will be critical
for development of vaccines (36, 37), as well as treatments
against schistosomiasis associated pulmonary hypertension (38).
Schistosomula Migration
The precise timing of schistosomula lung migration in humans is
not well understood. In a human model of S. mansoni skin
infection, transformed cercariae were seen in the epidermis 4
hours after exposure, remaining there for over 24 hours, before
moving through the dermis and hypodermis to the blood vessels
by 48-72 hours post infection (39). The timing of human skin
migration by S. haematobium is comparable to S. mansoni,
entering the dermis at around 48 hours post infection. In
comparison, S. japonicum human skin migration occurs much
faster, with the majority of schistosomula reaching the dermis by
9 hours post infection (39). Schistosomula lung migration, larval
maturation and pairing then occurs over a number of weeks,
with initial egg production evident in faeces or urine by 5-7
weeks post infection in humans (6). Understanding what occurs
in these weeks can be informed by primate models, in which
tracking studies are possible. In baboon primary infection, S.
mansoni larvae remain in the skin at day 2 post infection, moving
to the lungs by day 5, with the majority having left the lungs and
detectable in the liver by day 9 (40). To our knowledge, primate
tracking studies of larval migration have not been performed for
S. japonicum or S. haematobium infection.
Murine models have also been used to study larval migration,
with skin migration in mice following a similar timeline toFrontiers in Immunology | www.frontiersin.org 3humans. In primary infection studies, S. mansoni penetrates
the epidermis in minutes (2, 41, 42), but then takes
approximately 72 hours to migrate, first to sebaceous glands or
epidermal ‘migration channels’, then to the connective tissue of
the dermis and hypodermis, before penetration of blood vessels
as confirmed by histological analysis of skin sections (43).
Schistosomula are then swept in the blood system to the heart,
where they travel into the pulmonary circulation (44). Utilising
histological analysis as well as autoradiography of infected mice,
S. mansoni has been found in the lungs from day 4, peaking at
day 10-12, and steadily declining until approximately day 20,
when they start to be detectable in the mesenteric vessels and
liver (43, 45). Larvae may make multiple circuits of the
vasculature before reaching the portal system (35). Timing in
other species differs, with S. japonicum arriving in the lungs
earlier, peaking at day 3 (46), and S. haematobium migrating
more slowly, arriving in the lungs at day 7 (47).
Symptoms and Immunology of
Acute Schistosomiasis
Acute schistosomiasis, or Katayama syndrome, can occur any
time between 2 to 12 weeks post infection, which encompasses
larval migration and initial egg deposition (7). Katayama
syndrome has been reported to occur in the majority (over
50%) of travellers infected with Schistosoma spp., but is rare in
endemic individuals in schistosomiasis affected countries (15,
48). One explanation for this striking disparity is that endemic
locals are exposed to schistosome antigens and/or antibodies in
utero, causing a subsequent modulated immune response (49).
The predominant pulmonary symptoms observed in
Katayama syndrome are cough and lesions observed on lung
radiographs (15, 23). Radiographically observed lung lesions
have the capacity to self-resolve, or can be treated with the
anthelmintic praziquantel (50). These lesions, caused by immune
cell infiltrates, take on a variety of different forms, from a diffuse
interstitial pattern to nodular ‘ground glass’ presentations (12).
The variety in lesion presentation has been proposed to be
related to the stage of the disease (12). For instance, early,
diffuse infiltrates may result from a systemic hypersensitivity
response to migrating and maturing larvae, with morphological
features of eosinophilic pneumonia, as seen in other parasitic
lung infections (15, 51). These lesions have been observed in
patients as early as 4 weeks post infection, and can occur prior to
eggs being detectable in stool (15, 52). Nodular lesions have been
shown to occur in response to clusters of schistosome eggs, with
histological analysis of lung biopsies revealing eosinophilic
granulomas surrounding these eggs (53). However, recent
studies have supported the idea that egg deposition is not
required for Katayama syndrome (54, 55).
In travellers infected with an unusual S. haematobium/S.
mattheei hybrid, shown to be infertile, symptoms of acute
schistosomiasis developed 16-41 days post exposure, with
fever, muscle ache and cough the most common symptoms
(present in 50-69% of patients). Notably, schistosome eggs
were not detected in stool or urine (via PCR or microscopy),
although parasite infection was confirmed by PCR on serum
(55). Katayama syndrome also occurred in a pioneering study ofApril 2021 | Volume 12 | Article 635513
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alone (preventing egg production) (54), although only 1 out of 17
(6%) of the volunteers experienced pulmonary symptoms
(cough) (56). These cases are supported by multiple reports
documenting acute schistosomiasis as early as 2 weeks post
infection, when egg production has not yet begun (57, 58).
Chest radiographs were not performed in these studies, and so
the presence of lung lesions could not be determined.
Post-patent acute schistosomiasis displays characteristic
immunological features, with the majority of patients
presenting with significantly increased blood eosinophilia,
peaking in the initial stages of egg production, at 4-6 weeks
post infection (57, 59). Eosinophils are known to produce a
number of substances, including prostaglandin E2 and substance
P, that may induce coughing, potentially explaining this
symptom (60). Notably, in human infection with single sex
parasites, peripheral blood eosinophilia was also observed in
65% of volunteers, peaking between weeks 4-8, suggesting adult
worms are sufficient to drive eosinophilia even in the absence of
egg production (54, 56). Observational studies have also shown
increased total blood leukocyte levels towards the end of the
acute phase (8-12 weeks post exposure) (59). In addition to this,
immune complexes (formed by multiple antibodies binding
antigen) have been observed from 8 weeks post exposure in
55-93% of people with acute schistosomiasis, but are absent in
non-infected controls (61). S. mansoni egg antigens may be
critical for these immune complexes, as supported by work
showing immune complex levels are correlated with stool egg
counts, and first appear in murine models at day 35 post
infection, when initial egg production is expected (62, 63).
Circulating immune complexes during post-patent acute
schistosomiasis have been shown to be positively associated
with the pulmonary symptoms of cough, dyspnoea and
interstitial infiltrates observed in chest radiographs (64),
suggesting a potential causative link. A strong correlation was
observed between S. mansoni faecal egg counts and severity of
symptoms of acute schistosomiasis, suggesting that infection
load is a key influencer of the condition (57).
Immunologically, acute human schistosomiasis has
traditionally been proposed to be a type-1 dominated response
(24). Key evidence for this is a study showing secretion of the
type-1 associated cytokines IL-1, IL-6 and TNFa elevated in
unstimulated PBMCs from patients with post-patent acute
schistosomiasis (4-9 weeks post exposure), in comparison to
patients with chronic disease (64). However, Th2 responses were
not thoroughly investigated in this paper, with only one Th2
cytokine (IL-5) assessed, detectable in PBMCs from acute
schistosomiasis patients stimulated with schistosome egg
antigen (SEA) or schistosome worm antigen (SWA). Without
healthy controls reported, it is impossible to know if the levels of
IL-5 were increased compared to baseline (64). Further studies,
with a broader range of Th2 cytokines, are required before the
immunological bias of acute human schistosomiasis can be
confidently stated.
Evidence for a mixed pro-inflammatory/type-1 and Th2
immune response in pre-patent acute schistosomiasis comesFrontiers in Immunology | www.frontiersin.org 4from experimental human infection with single sex parasites.
In this study, serum levels of inflammatory and type-1 associated
chemokines macrophage inflammatory protein 1b (MIP-1b) and
interferon gamma induced protein 10 (IP-10) were increased at
week 4 post infection, with an increase in MIP-1b correlated to
symptoms of acute schistosomiasis (56). However, this study also
provided evidence for the importance of the Th2 response in
acute schistosomiasis, with antigen-specific Th2 (IL-4, IL-5 and
IL-13), but not Th1 (IFNg), CD4+ T cells at week 4 post infection,
significantly correlated to acute symptoms (56). This
prominence of the Th2 response is consistent with multiple
previous reports of eosinophilia during pre-patent acute human
schistosomiasis, with eosinophils often regarded as a type-2
effector cell (57, 59, 65).
Much less is known about immune responses to migrating
and maturing larvae at 0-3 weeks post infection, perhaps due to
the difficulty of identifying individuals so soon after exposure.
Symptomatic acute schistosomiasis can first occur from 2 weeks
post exposure (66), suggesting immune responses may begin at
this early stage. Some insight into the human response to
schistosomula may be gained from a study of infected endemic
individuals where PBMC responses were measured to
recombinant schistosomula antigens. These antigens provoked
type-1 and proinflammatory (including IFNg, IL-1b, TNFa), as
well regulatory (IL-10, IL-1Ra) cytokine responses (67).
Although informative, it is not clear whether the response to
these antigens, chosen due to their identification as vaccine
targets, is representative of the overall response to migrating
larvae in natural infection. Moreover, responses to these antigens
may be altered by their continued expression in adult stage
worms (68). Further studies of immune responses during human
pre-patent acute schistosomiasis are required to better
understand this phase of the disease.
Immunology of Acute Schistosomiasis in
Murine Models
Although most murine studies have focused on primary
infection, repeat or “trickle” infections beginning in childhood
are more likely to represent human schistosome interactions in
endemic populations (69). However, one issue with studying
repeat infections over a long time period in mouse models is that
egg-induced responses can modify the hepatic vasculature,
impairing the ability of schistosomula from subsequent
infections to lodge and mature in the liver. This means that
parasites can instead end up in the lung vasculature, where they
are eliminated, presumably mediated by the immune response
(70). This “leaky liver” model of resistance to reinfection is not
thought to be replicating the state observed in chronic human
infections, which has perhaps discouraged the use of murine
infection beyond primary infections or repeated infections over a
shorter time period (71). In addition, there has been much debate
on how to best mimic “natural” infectious doses in mouse
models. Controlled infection studies of non-endemic
individuals showed that infection with 10-30 cercariae was
sufficient to lead to diagnosable infection in all volunteers and
infection intensity levels comparable to those seen in a lowApril 2021 | Volume 12 | Article 635513
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infectious doses used in numerous murine studies, which tend to
range from 20 – 80 cercariae (24). However, more caution is
likely needed when interpreting reports that have used very high
doses of parasites (up to 500), which may partially explain some
previously highlighted immune response disparities between
humans and murine models (73). Importantly, it should be
emphasised that few reports (regardless of infection dose) have
studied lung-stage immunity closely and that additional research
is needed to understand how infectious dose alters early immune
events in the lung. These considerations must therefore be met
with pragmatism: “pushing the system” with an increased
primary infectious dose may be required to observe, and
therefore mechanistically interrogate, the fundamentals of the
immune response to schistosome larvae.
One distinct advantage of murine models is the ability to
dissect in vivo responses to the parasite at defined timepoints
post infection. However, in comparison to the wide literature
that exists addressing liver, spleen, and mesenteric lymph node
immune responses during murine schistosomiasis, relatively few
studies have investigated the lung stage of infection. Assessment
of thoracic (lung draining) lymph node T cell responses during
schistosomula lung migration revealed a significant increase in
Th2 cell IL-4 expression, but not Th1 cell IFNg, at days 14 and 21
post 70 cercariae infection (32). It has also been suggested that
promotion of Th2 responses by larval antigens may prime the
immune response in advance of egg deposition, aiding both host
and parasite survival (74). Additional studies utilising state of the
art techniques to expand this limited understanding of
pulmonary inflammation during schistosome migration are
sorely needed.
Older histological studies have, in high dose (450 cercariae)
infections, observed inflammatory foci consisting of neutrophils,
eosinophils, macrophages and lymphocytes around lung
migrating S. mansoni larvae at days 7-31 post infection (14).
Notably these foci were not seen surrounding intravascular
parasites, but only those that had entered the alveolar space,
supporting a model in which “failed” intra-alveolar larvae, which
have burst out of the narrow lung capillaries, may be the main
drivers of pulmonary inflammation against migrating parasites
(14, 35).
Similar results were observed during high dose (400-500
cercariae) murine infection with S. japonicum, with leukocyte,
macrophage and eosinophil infiltration observed in murine lungs
from 3-5 days post infection (75). In addition to this,
histopathological changes were observed in the lung
parenchyma and vessels, with vasculitis, haemorrhage and
parenchymal involvement from 5 days post infection (75). No
direct association between intravascular larvae and immune
infiltration was noted, potentially suggesting a non-specific
damage response, a hypothesis supported by transcriptional
data from lung tissue, in which upregulation of wound healing
genes was observed (75). In addition to this, lung inflammatory
gene signatures increased post infection, including chemokines
CCL7, CCL17 and CCL2, as well as the gene Retnla (Resistin Like
Molecule alpha, RELMa), which is commonly upregulatedFrontiers in Immunology | www.frontiersin.org 5during type-2 inflammation (75). Further work is required to
understand which pulmonary cell types are responsible for the
upregulation of these mediators, and their potential functional
roles, with our current understanding of innate cells particularly
lacking in this context.
Finally, systemic immune parameters measured during
murine lung migration have also been used to proxy
pulmonary immune responses to schistosomula. 2-4 weeks
post infection with 40 cercariae, S. mansoni antigen stimulated
splenocytes show increased expression of IFNg, as well as the
Th2 cytokines IL-5 and IL-4, when compared to uninfected
controls (25, 74). Looking slightly earlier, at day 9 of 100-150
cercariae S. mansoni infection, an increase in plasma levels of the
Th17 associated cytokine IL-17, in addition to the Th2 cytokine
IL-4 and the Th1 promoting cytokine IL-12p70, was observed
(76). Although of reduced relevance to pulmonary responses,
systemic measurements are more easily comparable with human
studies, in which blood is often the most accessible sample.
Immune Evasion by Lung Migrating
Schistosomula
When considering how schistosomula may evade the immune
response while migrating through the lung, the anatomical
structures of the airways and vasculature must be considered.
It is unclear whether pulmonary migration is beneficial for the
parasite, or instead an inconvenient obstacle to bypass. Both
tissue resident and circulating immune cells patrol the lower
airways and lung capillaries. However, in order for the lungs to
constantly carry out their vital physiological role of respiration,
immune responses in the lower airways are tightly controlled to
maintain homeostasis (77). A wide array of pulmonary innate
defences against common airborne pathogens are therefore
instead concentrated on the upper airways (78). The regulatory
bias of immunity in the lower airways may provide a relatively
protected environment for larval development, proposed to
explain why larval lung migration is a feature of multiple other
helminth life cycles (78). Another important consideration is the
constant movement of larvae within the vasculature, which may
make localising a focal immune response by patrolling immune
cells, such as neutrophils, more difficult (79). Thus, their
intravascular niche, in combination with motility and relatively
rare ‘rupturing’ into the airways, may together help limit
inflammation around the migrating schistosome larvae.
On the other hand, the time taken for schistosomula to transit
through murine lung capillary beds, 30-35 hours in comparison
to 6-16 hours in systemic and intestinal capillary beds, suggests
the lung may present a unique migratory obstacle (80). After
arriving in the lung, 18mm wide schistosomula (81) must narrow
and elongate to bypass thin walled and 6mmwide lung capillaries
(82). Schistosomula must remain entirely intravascular for
successful migration, as rupturing into the alveoli risks them
being swept up the airways, swallowed and digested (83).
Moreover, damage caused by rupturing into the alveolar space
may invite immune attack (14).
Schistosomes employ numerous mechanisms in order to
evade immune attack, as detailed below, and recently reviewedApril 2021 | Volume 12 | Article 635513
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host antigens, including blood group antigens and major
histocompatibility (MHC) proteins, in order to block binding
of host anti-schistosomula antibodies (85–87). In adult worms
this has been shown to be an active process, with coating of
human low density lipoprotein (LDL) dependent upon specific
binding to parasite receptors (88). However, unlike adult worms,
when this defence is overcome via addition of anti-host antibody
to lung stage schistosomula in vitro, larvae are still resistant to
immune killing (85). This could be explained by an intrinsic
resistance of lung stage schistosomula to antibody dependent
killing, potentially due to ongoing breakdown and biosynthesis
of schistosomula membrane sphingomyelin allowing access of
small molecules, but not antibodies, to the parasite surface (89,
90). Intrinsic properties of the schistosomula outer coat
(tegument) may allow it to resist immune attack, as they
rapidly acquire a protective outer lipid bilayer, referred to as
the membranocalyx, during development from cercariae (91–
93). In addition, schistosomula are able to evade complement
killing via the acquisition of host decay accelerating factor
(DAF), which prevents assembly of complement convertases
critical for both the alternative and classical pathway of
complement activation (94).
As well as acquisition of host products, the parasites
themselves produce molecules that may contribute to immune
evasion. As schistosomula predominantly stay intravascular, they
have been found to suppress immune activation of lung
endothelial cells (95). Specifically, schistosomula can interfere
with the NF-kB pathway in endothelial cells, reducing expression
of the integrins e-selectin and vascular cell adhesion molecule 1
(VCAM-1), critical for immune cell migration, in response to
TNFa (95). Additionally, a recent transcriptomics study
reported upregulation of genes associated with immune
evasion in in vivo isolated lung S. mansoni schistosomula,
including genes involved in defence against oxidative stress,
potentially minimizing inflammatory effects of reactive oxygen
species (ROS) (68). The same study revealed that lung migrating
larvae upregulate arginase expression, which can interfere with
host nitric oxide (NO) production, thereby suppressing both
macrophage and T cell activation (68, 96). Finally, lung stage S.
mansoni schistosomula, in comparison to maturing larvae
isolated at day 13-21, show increased expression of kunitz
protease inhibitor, a molecule with putative anti-coagulation
and anti-inflammatory ability that is also expressed in the
adult worm tegument (68, 97). Further work is required to
establish the location of these proteins within the
schistosomula, with those expressed on the tegument, in
contact with the host environment, of particular interest in
relation to immune evasion.
Intriguingly, regulatory T cell (Treg) expansion does not
appear to occur during schistosomula lung migration (32).
This is in comparison to larval stages of nematode infections,
where Tregs are induced to modulate the host’s immune system,
aiding parasite survival (98–101). It is possible that immune
modulation against schistosome larvae is instead mediated by the
regulatory cytokine IL-10, which is increased in thoracic lymphFrontiers in Immunology | www.frontiersin.org 6node Th2 cells during larval migration of S. mansoni (32).
Mechanistic experiments, for instance depleting IL-10 or Tregs,
are required to direct ly address i f they play any
immunoregulatory role during S. mansoni larval lung migration.
Lung Stage Schistosomes as a
Vaccine Target
The hope that immunity to schistosomes is possible is supported
by the observation that intensity of infection decreases with age,
suggesting a build-up of at least partial immunity over time
(102). Moreover, correlates of natural immunity have been
observed in humans, including type-2 immune factors such as
IgE and eosinophils (103–105). It is possible such factors may
mediate schistosome killing during their transit through the
lung. Indeed IgE responses may be specific to antigens released
from dying worms that may cross-react with antigens of
invading larvae (106). However, induction of IgE based
immunity is not an advisable route for vaccine induced
protection, due to the risk of initiating generalised allergic
responses, as has been observed in hookworm vaccine trials
(107). Alternative strategies to induce protective immunity are
therefore required.
Lung migrating larvae have been shown to be the target for
protective immune response in mice vaccinated with radiation
attenuated (RA) cercariae (14). Radiation treatment decreases
larval motility whilst enhancing immunogenicity, allowing the
host immune system to mount an immune response that is
protective against subsequent infection (108, 109). In non-
vaccinated mice parasite survival is around 30%, whereas in
vaccinated mice parasite survival to adulthood can be as little as
4%, depending on a number of factors, including the number or
vaccinations as well as radiation dose (110, 111). One study
utilising a large infectious dose (450 cercariae), found that
immune foci surrounding migrating larvae, in comparison to
non-vaccinated mice, are larger and observed around both intra-
vascular and intra-alveolar parasites, and are thought to block
migration (14, 112, 113). Blocking migration may be a
particularly effective strategy to inhibit parasite development,
bypassing the innate ability of schistosomula to evade immune
killing (37, 114).
Much of our understanding of protective immunity against
lung migrating schistosomula has come from studies that
undertake challenge re-infection post vaccination with RA
cercariae (115). A number of non-redundant mechanisms are
thought to be required for protection, including CD4+ T cell
immunity, specifically Th1 cell secretion of IFNg, pulmonary
macrophage activation and NO production, which can result in
up to 70% protection against challenge re-infection (116–119).
However, it appears that it isn’t as simple as Th1 responses
being most effective for vaccine protection, as repeat exposure
to RA cercariae induces a Th2 dominated response, and
promotes higher levels of protection (>80%) than the Th1-
promoting single exposure (120, 121). Further, mice deficient
in the IL-4 receptor subunit alpha (IL-4Ra) that develop
elevated Th1 responses and impaired Th2 immunity, display
reduced vaccine protection, likely due to a reduction in IgG1April 2021 | Volume 12 | Article 635513
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likelihood that both Th1 and Th2 responses are required for
optimal protection in the RA vaccine model, further supported
by the fact that protection is enhanced in IL-10 deficient mice,
which exhibit elevated Th1 and Th2 responses (123).
Mechanistically, what dictates Th1 versus Th2 immunity to
RA parasites is not fully understood, but likely depends upon
the influence of vaccination dose and frequency on the balance
of the immune response that develops (120). Taken together,
although the constituents of a protective immune response are
still controversial, a robust, mixed Th2/Th1 response may
be optimal.
The success of the RA vaccine has led to investigation of
lung stage specific antigens in vaccine development (36, 37).
Recent work has focused on targeting antibody-accessible
schistosomula excretory secretory products, in combination
with a Th2 adjuvant (IL-25 or IL-33), with around 70%
protection elicited in murine models (124). However, this
study had a very short timescale (14 days) between
vaccination and challenge with vaccine candidates and so
should be treated with caution, as an active immune
response to the vaccine would likely still be present at time
of challenge. Extending intervals between vaccination and
challenge, as well as utilising models with more human-like
lung capillary networks, such as non-human primates, are
suggestions that have been made to improve the relevance of
future tests of lung-stage antigens (111).
Lung Symptoms in Chronic Schistosomiasis
Pulmonary symptoms can also occur in individuals with chronic
schistosomiasis, including lung lesions (observed in chest
radiographs), and pulmonary hypertension (22, 23). Pulmonary
hypertension is a potentially fatal complication of hepatosplenic
disease, occurring in 6.3-13.5% of patients (21, 22). Strikingly, the
five year survival rate of untreated individuals with schistosome
associated pulmonary arterial hypertension is 69.2% (38). Liver
fibrosis due to egg deposition causes portal hypertension that can
directly cause pulmonary hypertension (18). Additionally, portal
hypertension may lead to the formation of porto-systemic venous
shunts, allowing eggs to pass to the lungs, observed both in mice
(19) and humans (20). Eggs, or even adult worms, that translocate
through these shunts to the lung may obstruct the pulmonary
vasculature, either directly or as a result of the host inflammatory
response (17, 125). These are thought to be responsible for lung
lesions observed via chest radiograph, and have been found by
histological examination of lung biopsies (23). The clinical
importance of pulmonary symptoms in chronic schistosomiasis
necessitates increased understanding of the underlying
immune responses.
Lung Immunology of Chronic
Schistosomiasis in Murine Models
Murine models of chronic pulmonary schistosomiasis have been
developed, in order to better understand the condition and guide
future treatments (33). Early studies used surgical ligation of the
portal vein to create a shunt from the portal system to the lungs,Frontiers in Immunology | www.frontiersin.org 7in order to increase egg translocation to the lungs (126). Utilising
this model, granulomas, macrophage and eosinophil rich
structures enclosing the eggs, were found in the lungs 10-25
weeks after 50 cercariae S. mansoni infection (127). However,
these granulomas remained similar in size and cellular
consti tuents over the 10-25 week t imescale (127).
Immunological modulation (especially decreased granuloma
size) is a characteristic feature of liver granulomas (128), and
its absence in the surgical ligation model may therefore be a
fundamental limitation.
It is possible to model pulmonary effects of chronic
schistosomiasis without portal vein ligation. Substantial lung
egg deposition peaks at week 17 in mice infected with 30
cercariae, with an average of 189 eggs per lung lobe (33).
Notably, this is still vastly reduced in comparison to liver egg
deposition, which contains over a million eggs at this timepoint
(33). Lung inflammation was observed as an increase in immune
cells (especially CD68+ macrophages) in granulomas and in
perivascular regions (33). The degree of pulmonary vascular
remodelling was associated with lung egg burden, supporting
the hypothesis that egg deposition contributes to vascular
changes seen in human schistosome induced pulmonary
hypertension (22, 33). In chronically infected mice, at week 17
post infection, there was a significant positive correlation
between numbers of lung eggs and expression of the Th2
cytokine IL-13, suggesting eggs are driving a pulmonary type-
2 response (34). The type-2 cytokine IL-4 also increased in the
lung in week 17 infected mice, in combination with the type-1
associated cytokines IL-12p70 and TNFa (34). How these
different arms of the immune response contribute to the
development of pulmonary hypertension in this model is still
to be determined.
Pharmacological and genetic intervention studies have
shown the importance of immunological processes in
regu l a t ing pu lmonary egg depos i t i on in chron i c
schistosomiasis. In B cell deficient mice, or mice treated with
IL-10R blockade, increased pulmonary egg deposition was
observed at 16 weeks post infection, associated with extensive
lung cel lular infi l tration (129). This indicates that
immunoregulation mediated by IL-10 or B cells may reduce
egg translocation to the lungs. In addition to this, mice that
have impaired Th2 development, due to transgenic deletion of
the costimulatory molecule CD154, display early egg
translocation to the lung during S. mansoni infection, before
week 8 (130). In this study, CD154-/- mice also displayed
reduced iNOS expression, indicating that alterations in
vascular mediators such as NO may underlie the increase in
pulmonary egg deposition that was observed (130).
Increased definition of the impact of other infection
associated immune mediators on the vasculature may be
critical to help understand the importance of B cells, IL-10 and
Th2 immunity in regulating pulmonary egg deposition. A central
role for the vasculature in these processes was reinforced by a
recent study, in which schistosome infected mice with
heterozygous deletion of Bmrp2 (bone morphogenetic protein
type-II receptor, BMPR-II), the most common genetic cause ofApril 2021 | Volume 12 | Article 635513
Houlder et al. Schistosomes in the lungpulmonary arterial hypertension (PAH), had enhanced
pulmonary egg deposition. In this model, dilated hepatic veins
and sinusoids in heterozygous deleted BMPR-II mice increased
the ease of portal shunting, leading to elevated pulmonary egg
deposition and lung IL-13 cytokine levels (34). Such data
strongly indicate that development of novel treatments for
schistosome induced pulmonary hypertension will require
increased understanding of the critical mediators involved in
the interplay between egg-driven inflammation and the
vascular system.
The pulmonary immune response to S. mansoni eggs can
also be modelled by experimental egg injection, where mice
are injected intravenously (i.v.) with live or cryopreserved
eggs, normally following pre-sensitization with eggs injected
intraperitoneally (i.p.). In this model, following i.v. injection,
schistosome eggs become lodged in the lungs where they
initiate formation of granulomas and production of Th2-
biased cytokines (131, 132). This reproducible model
for Th2-driven lung inflammation, far quicker than the
16 week+ chronic models of infection, has greatly increased
our understanding of Th2-mediated lung granuloma
responses (118, 133–135). During chronic infection,
pulmonary immune responses to schistosome eggs occur in
the context of a pre-existing immune response to larval, adult
and egg antigens, which cannot be replicated by experimental
egg inject ion alone. However , comparison of both
models may provide substantial insight into the regulation
of type-2 immune responses by natural infection, potentially
t r a n s l a t i n g t o t h e r a p e u t i c b e n efi t s i n c h r o n i c
schistosomiasis (136).Schistosomiasis and Impact on Allergic
Lung Inflammation
Finally, it has been shown that chronic schistosomiasis may
regulate pulmonary inflammation during other conditions, such
as allergy. Atopic diseases common in high income countries are
relatively reduced in lower income countries that have the
highest intensity of schistosome infections (1, 137). This
inverse correlation between atopy, measured by skin prick test,
and schistosome infection in endemic areas (138) has led to
suggestions that schistosomiasis protects against lung allergic
inflammation. The immunomodulatory properties of helminth
infection have been extensively reviewed (139, 140). Murine
models have shown chronic S. mansoni infection induces
regulatory mechanisms that suppress allergic airway responses
to model allergens (141). IL-10 producing regulatory B cells
(Bregs) are proposed to be key mediators of immune regulation
in chronic S. mansoni infection, with transfer of Bregs from
schistosome infected mice sufficient to reduce allergic airway
inflammation (31, 142–144). Expansion of IL-10 producing B
cells has also been observed in human S. haematobium infection,
reduced after praziquantel treatment (31). Notably, the influence
of migratory larval stages of schistosomula on allergic conditions
is not yet known.
This aspect of infection may be critical to consider in endemic
areas, where regular exposure to infected water may make lungFrontiers in Immunology | www.frontiersin.org 8migrating schistosomula key influencers of the pulmonary
immune responses.CONCLUSIONS AND FUTURE OUTLOOK
Despite the clear pathological consequences of schistosome
infection on the lungs, there has been a relative scarcity of
refined research into this area in recent years. In both acute
and chronic phases, schistosomiasis has debilitating and even
fatal pulmonary consequences (7, 22, 52). Immune responses are
thought to be responsible for many of the symptoms of
pulmonary schistosomiasis, for example the correlation of
immune complexes to cough, dyspnoea and interstitial
infi l t rates observed in chest radiographs in acute
schistosomiasis (64). Nonetheless, despite the groundwork
being laid by formative older studies of pulmonary
schistosomiasis, both in mouse and human (14, 17, 64), our
knowledge on this subject is not up to date with the sophisticated
and detailed view of the immune system held today.
Despite the many outstanding questions that remain
regarding pulmonary schistosomiasis – see Box 1 – several
recent studies that have increased our understanding in this
area. For example, the older dogma of acute schistosomiasis as a
Th1 dominated response is being questioned by more recent
research showing early Th2 cytokine responses in thoracic lymph
nodes (32). A focus on T cell responses, often systemic, has
meant that there is a notably limited understanding of innateApril 2021 | Volume 12 | Article 635513Box 1: Outstanding questions
• Which specific aspect of infection (lung migrating larvae, maturing larvae,
egg deposition) account for the varied symptoms that can be seen
during acute schistosomiasis (e.g. cough, fever)?
• What are the precise kinetics of schistosome lung migration in humans?
Increased understanding could be gained by combining experimental
human infection studies with research into stage-specific antigens.
• How common is symptomatic acute schistosomiasis in endemic
populations? Symptomatic acute schistosomiasis may be under-
reported in endemic areas, an issue that could be clarified by more
studies of initial exposure in childhood.
• What is the cause of radiographically observed pulmonary lesions in
acute schistosomiasis?
• How is the switch between acute and chronic schistosomiasis defined
immunologically and symptomatically?
• What are the immunological hallmarks of pulmonary schistosomiasis?
Studies in this area have not kept up with either conceptual or technical
developments in cellular immunology. For example pulmonary dendritic
cell and macrophage cell subsets are thought to be critical for initiation
and regulation of immunity, yet which promote or regulate tissue
damage against lung stage infection?
• What constitutes a protective immune response in schistosomiasis, and
how might we induce this in vaccine studies? Are lung migrating
schistosomula suitable targets for vaccine responses?
• How might the immunoregulatory strategies of lung migrating
schistosomula be overcome for vaccine or therapy development? On
the other hand, might these mechanisms be harnessed to calm over-
exaggerated immune responses in inflammatory pathologies?
• Are immunological responses centrally involved in the development of
pulmonary hypertension in chronic schistosomiasis? If so, how might
this be manipulated therapeutically?
Houlder et al. Schistosomes in the lungimmune responses in lung tissue in both acute and chronic
schistosomiasis. In terms of our understanding of human
immune responses, controlled human schistosome infection
studies have an enormous potential to reveal acute stage
pulmonary responses (56). Understanding these responses will
be critical to direct the development of novel vaccines or
therapeutics for schistosomiasis, as well as the numerous other
parasitic infections causing pulmonary pathology (51).
Moreover, improved mechanistic understanding of how
s c h i s t o s om e s p r omo t e o r r e g u l a t e p u lmon a r y
immunopathology could also help with rational design of
future therapies against diverse lung diseases.AUTHOR CONTRIBUTIONS
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